BVT Bonus Zert GILD 31.12.2024/ DE000VM96JK4 /
| 04/09/2024 08:38:24 | Chg.+0.14 | Bid22:00:40 | Ask22:00:40 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 88.26EUR | +0.16% | - Bid Size: - |
- Ask Size: - |
Gilead Sciences Inc | - USD | 31/12/2024 | Call |
GlobeNewswire
08/08
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
08/08
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
GlobeNewswire
08/08
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
GlobeNewswire
06/08
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire
01/08
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
23/07
ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...
GlobeNewswire
15/07
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...
GlobeNewswire
01/07
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
01/07
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
28/06
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
26/06
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
26/06
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
18/06
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
10/06
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
